In this episode of LATAM MedTech Insights, we demystify the process of registering a foreign-made AI medical device in Mexico. As one of Latin America's largest and most promising markets, Mexico presents a significant opportunity for MedTech innovators. However, its regulatory body, COFEPRIS, has unique requirements that can stall market entry if not navigated correctly. We explore why COFEPRIS treats AI and Software as a Medical Device (SaMD) differently than other global agencies and reveal the single most effective strategy for expedited approval: the Equivalency Agreement. Learn how leveraging your existing FDA, Health Canada, or Japan MHLW clearance can cut your registration timeline in half. We will walk through a real-world case study of a U.S. company that successfully used this pathway, highlighting the critical documents and local requirements they needed to succeed. **This episode's key questions:** - What is the number one mistake foreign companies make when classifying their AI medical device for COFEPRIS? - How can your existing FDA clearance reduce your Mexico market entry timeline from over a year to just a few months? - Why is a Mexican Registration Holder (MRH) legally mandatory before you even submit your application? - What are the specific translation and labeling requirements that COFEPRIS strictly enforces? - How does the risk classification for a software-only device work without a physical component? - What common post-market surveillance duties for AI devices in Mexico often go overlooked? - Are there hidden fees in the COFEPRIS registration process that can surprise foreign applicants? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. If you're looking to enter the complex but rewarding Mexican market, let our experts guide your strategy. Contact us at [email protected] or visit https://pureglobal.com/ for more information.